Detection of Endometrial Cancer Through Risk Modelling
Recruiting now NCT06268626
Run by University of British Columbia · for 40 and older · Women · accepts healthy volunteers
What this study is about
The study goal is to investigate a non-invasive approach to predict endometrial cancer (EC) risk, better understand disease progression and identify opportunities for intervention. This two-part case-cohort prospective study will recruit patients whose abnormal uterine bleeding is being evaluated via endometrial biopsy. Participants will complete an online health questionnaire, and a subset will be invited to self-collect vaginal samples for sequencing. Selected sequenced participants will be invited for longitudinal monitoring (questionnaires, wearable fitness tracker) and an additional vaginal self-collection to identify persistent genetic mutations or microbiome alterations 6-8 months later.
Who can join (things the study team will check)
✅ You may be able to join if…
- 40 years and older
- Experiencing unexplained abnormal uterine bleeding (i.e., not from IUD, etc.)
- Have an intact uterus
- Referred for an endometrial biopsy Study Part B/Longitudinal monitoring:
- Those selected for sequencing (from Part A) and who retained their uterus.
🚫 You may not be able to join if…
- Endometrial sampling, pelvic radiation, or vaginal infection (vaginosis, yeast) in the past 3 months
- Started hormone therapy (HRT, birth control, IUD) in the past year (with the exception of tamoxifen)
- Intercourse, vaginal product use, or douching in the past 48 hours Study Part B/Longitudinal monitoring:
- Same as Study Part A
- EC or EIN, or anyone who is recommended a hysterectomy
Where this trial is running
- VGH Research Pavilion, Vancouver, British Columbia, Canada
Who to contact
Aline Talhouk, PhD · +1 (604) 875-4111 · a.talhouk@ubc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06268626.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.